AFRM vs CIB

AFRM's Piotroski F-Score of 7/9 indicates strong operational health, but the absence of an Altman Z-Score raises concern about bankruptcy risk, particularly given a high Debt/Equity ratio of 2.59. The stock trades at a premium valuation (P/E 57.88 vs. sector average 30.46) despite mixed earnings quality, with recent Q/Q EPS growth at +213% but year-over-year EPS down 5.3%. Insider selling totaling $56.66M in the last six months signals bearish sentiment from management. While revenue and earnings growth remain robust (29.6% and 59.3% YoY), the lack of cash flow data and high leverage undermine financial stability. The current price of $46.88 is significantly above both the Graham Number ($13.95) and intrinsic value estimate ($23.9), suggesting a substantial valuation premium driven by growth expectations.

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration in financial fundamentals. While the stock has shown impressive long-term price appreciation and maintains a strong ROE of 16.96%, current growth metrics are catastrophic with YoY revenue down 80.10% and earnings down 72.30%. The stock is currently trading at $71.51, which is significantly above its growth-based intrinsic value of $55.30 and the analyst target price of $63.76. Despite an attractive dividend yield, the fundamental collapse outweighs the valuation appeal.